- Home
- MVST vs GHRS Comparison
MVST vs GHRS Comparison
Compare MVST & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | GHRS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MVST | GHRS |
|---|---|---|
| Price | $2.87 | $16.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $6.00 | ★ $32.90 |
| AVG Volume (30 Days) | ★ 4.5M | 684.4K |
| Earning Date | 11-10-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $444,504,000.00 | N/A |
| Revenue This Year | $24.19 | N/A |
| Revenue Next Year | $17.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.82 | N/A |
| 52 Week Low | $1.09 | $7.98 |
| 52 Week High | $7.12 | $20.50 |
Technical Indicators
Market Signals| Indicator | MVST | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 55.25 |
| Support Level | $2.78 | $15.98 |
| Resistance Level | $3.16 | $17.30 |
| Average True Range (ATR) | 0.22 | 1.28 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 11.62 | 50.00 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.